Medicare Part B: Lyfgenia (Lovotibeglogene Autotemcel)
Customize your policy alerts
Sign up for all MVP Health Care policy alerts
Know when MVP Health Care releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs Medicare Part B coverage and prior authorization for Lyfgenia, a one-time gene therapy for members aged 12 years or older with sickle cell disease and recurrent vaso-occlusive crises. Coverage requires specified clinical documentation, treatment at a Qualified Treatment Center, and fulfillment of hematologic, organ-function, infection, and transplant-related criteria.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.